modelLumiracoxib

Diagram of Lumiracoxib

Extends from Pharmacolibrary.Drugs.ATC.M.M01AH06.

Information

name:Lumiracoxib
ATC code:M01AH06
route:oral
compartments:1
dosage:400mg
volume of distribution:23L
clearance:6.37L/h
other parameters in model implementation

Lumiracoxib is a selective COX-2 inhibitor non-steroidal anti-inflammatory drug (NSAID) formerly used for relief of osteoarthritis and acute pain. It is no longer widely approved due to concerns over hepatotoxicity and has been withdrawn in most markets.

Pharmacokinetics

Pharmacokinetic parameters reported in healthy adult volunteers following single oral dose administration.

References

  1. Scott, G, et al., & Ruff, DA (2004). Pharmacokinetics of lumiracoxib in plasma and synovial fluid. Clinical pharmacokinetics 43(7) 467–478. DOI:10.2165/00003088-200443070-00003 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15139795

  2. Scott, G, et al., & Rordorf, C (2004). Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxib. Clinical pharmacokinetics 43(5) 341–348. DOI:10.2165/00003088-200443050-00006 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15080766

  3. Vásquez-Bahena, DA, et al., & Trocóniz, IF (2010). Pharmacokinetic-pharmacodynamic modelling of the analgesic effects of lumiracoxib, a selective inhibitor of cyclooxygenase-2, in rats. British journal of pharmacology 159(1) 176–187. DOI:10.1111/j.1476-5381.2009.00508.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/19958362

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.TransferRateka (from PK_1C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_1C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)